Last reviewed · How we verify
Naproxen Sodium + Codeine Phosphate
Naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and pain, while codeine phosphate acts as an opioid agonist to enhance analgesia through central nervous system depression.
Naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and pain, while codeine phosphate acts as an opioid agonist to enhance analgesia through central nervous system effects. Used for Moderate pain relief, Pain associated with inflammation.
At a glance
| Generic name | Naproxen Sodium + Codeine Phosphate |
|---|---|
| Sponsor | ibrahim doğru |
| Drug class | NSAID + opioid analgesic combination |
| Target | COX-1, COX-2, mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever. Codeine phosphate is an opioid analgesic that binds to mu-opioid receptors in the central nervous system to modulate pain perception. The combination provides synergistic pain relief for moderate to moderately severe pain conditions.
Approved indications
- Moderate to moderately severe pain
- Acute pain conditions requiring combined NSAID and opioid analgesia
Common side effects
- Nausea
- Dizziness
- Constipation
- Dyspepsia
- Drowsiness
- Gastrointestinal bleeding
- Respiratory depression
Key clinical trials
- Evaluation of the Analgesic Efficacy of the Combination of Dexketoprofen + Paracetamol and the Combination of Naproxen Sodium + Codeine in Patients With Acute Dental Pain (PHASE4)
- Efficacy of Naproxen-codeine, Naproxen+Dexamethasone, and Naproxen on Myofascial Pain (PHASE4)
- Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis (PHASE4)
- Naproxen Codeine in Arthroscopic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naproxen Sodium + Codeine Phosphate CI brief — competitive landscape report
- Naproxen Sodium + Codeine Phosphate updates RSS · CI watch RSS
- ibrahim doğru portfolio CI